US20010051735A1 - Derivatives of isosorbide mononitrate and its use as vasodilating agents with reduced tolerance - Google Patents

Derivatives of isosorbide mononitrate and its use as vasodilating agents with reduced tolerance Download PDF

Info

Publication number
US20010051735A1
US20010051735A1 US09/827,868 US82786801A US2001051735A1 US 20010051735 A1 US20010051735 A1 US 20010051735A1 US 82786801 A US82786801 A US 82786801A US 2001051735 A1 US2001051735 A1 US 2001051735A1
Authority
US
United States
Prior art keywords
group
mononitrate
isosorbide
compounds
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/827,868
Other languages
English (en)
Inventor
Jose Moliner
Francisco Coy
Lydia Llorente
Marcel.li Banus
Cristina Rofes
Juan Riudavets
Alicia Siso
Marek Radomski
Eduardo Perez-Rasilla
Juan Bonnin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lacer SA
Original Assignee
Lacer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lacer SA filed Critical Lacer SA
Assigned to LACER, S.A. reassignment LACER, S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BANUS, MARCEL.LI CARBO, BONNIN, JUAN MARTINEZ, COY, FRANCISCO PUBILL, LLORENTE, LYDIA CABEZA, MOLINER, JOSE REPOLLES, RADOMSKI, MAREK W., RASILLA, EDUARDO PEREZ, RIUDAVETS, JUAN ANTONIO CERDA, ROFES, CRISTINA NEGRIE, SISO, ALICIA FERRER
Publication of US20010051735A1 publication Critical patent/US20010051735A1/en
Priority to US10/424,828 priority Critical patent/US6858632B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to novel derivatives of isosorbide mononitrate which have a potent vasodilating activity and which, at the same time, have a significantly reduced tolerance.
  • nitric acid esters of organic compounds common known as nitrated organic compounds, are known and have been used as vasodilating agents.
  • nitrated organic compounds are known and have been used as vasodilating agents.
  • the usefulness of mono and di-nitrated isosorbide is well known, and further there have been described compounds with vascular and coronary activities based on substitution reactions of the free hydroxyl group of isosorbide mononitrate.
  • the U.S. Pat. No. 4,891,373 patent describes derivatives of aminepropanol corresponding to the formulas
  • R 5 represents a hydrogen atom, a C 1 -C 6 alkyl group, a phenyl, etc.
  • nitrated organic compounds described in the documents mentioned above do not in itself solve the problems originating from the tolerance of the nitrated organic compounds, since these still have problems in relation to low vasodilating activity, high tolerance, etc.. Accordingly, it is still necessary to develop novel nitrated organic compounds which have a high vasodilating activity combined with a more decreased level of tolerance being maintained persistently.
  • An object of the invention is a novel type of compounds, derivatives of isosorbide mononitrate, which are capable of providing a potent vasodilating effect and which at the same time show a small or null tolerance effect.
  • a further object of the present invention relates to the use of the novel derivatives of isosorbide mononitrate for the manufacture of a medicament for the treatment of disorders related to dysfunctions of the circulatory system, in particular at the level of the coronary system.
  • Z is an oxygen atom or sulphur atom
  • R is an alkyl C 1 -C 4 group, an aryl group or an aralkyl group, eventually substituted, or the group
  • R 1 is hydrogen or an alkyl C 1 -C 4 group, an aryl group or an aralkyl group, eventually substituted.
  • R is an alkyl C 1 -C 4 group, an aryl group or an aralkyl group, eventually substituted
  • R 1 represents the groups indicated above.
  • R when Z is a sulphur atom, R is a short chain C 1 -C 4 alkyl group, and when Z is an oxygen atom, R 1 is a hydrogen atom or a short chain C 1 -C 4 alkyl group. More preferably, within above mentioned criteria, B is the —ONO 2 group, i.e. the compounds wherein the nitrate ester is at position 5 in the ring-shaped system of the isosorbide.
  • the compounds of the present invention can be obtained by techniques of esterification using known or accessible starting products described in the basic organic chemical literature known to the skilled person, for example the publications of Chemical Abstracts Service, the Beilstein Encyclopedia of organic products, or in any other appropriate publication available at university libraries.
  • the compounds when Z is an oxygen atom the compounds may be obtained from isosorbide or the corresponding isosorbide mononitrate through a reaction of esterification of these with the corresponding carboxylic acid or an activated derivative of this, for example an acid chloride, an anhydride, an active ester, etc. If the starting product is isosorbide, it will be necessary finishing with a further step consisting of nitrating the free hydroxyl group of the isosorbide, a thing which is not necessary if there is started from any of the isosorbide mononitrates in position 5 or in position 2 of the ring-shaped structure of said compound.
  • R 1 is hydrogen
  • these compounds have a thiol group which can be unintentionally oxidized producing disulphur dimers.
  • the dimers can be reverted to the corresponding monomers by reaction with triphenylphosphine in water, as described in R. Humphrey (1964), Analytical Chem,36,1812 y L. E. Overman (1974), Synthesis, 59.
  • the compounds of the invention may very efficiently be used for the manufacture of a medicament with vasodilating effect for the treatment of dysfunctions of the circulatory system, in particular at the cardiovascular and coronary level.
  • the compounds of the general formula (I), as well as their pharmaceutically acceptable salts may be used, via the use of conventional pharmaceutical techniques, in the manufacture of medicaments which may be administrated by different routes.
  • compositions such as tablets, capsules, syrups and suspensions.
  • parenterally in form of solutions or emulsions, etc. may also be administrated topically in form of creams, pomades, balsams, etc., and transdermically for example through the use of patches or bandages. They may also be applied directly in the rectum as suppositories.
  • the preparations may comprise physiologically acceptable carriers, excipients, activators, chelating agents, stabilisators, etc. In case of injections there may be incorporated physiologically acceptable buffers, solubilizing agents or isotonics.
  • the daily dose may be varied depending on the specific symptoms, the age, the body weight of the patients, the specific mode of administration, etc., and a daily normal dose for an adult person could be between 1 to 500 mg, and could be administrated as one dose only or divided into several doses during the day.
  • Step 1 In a 50 mL glass flask, provided with a reflux refrigerator, closed with a CaCl 2 tube, and magnetic agitation, 4.25 g (23.2 mmol) 2-ethylthionicotinate acid are dissolved in 20 mL of thionyl chloride (1.64 g/ml; 275.6 mmol). The reaction mixture is refluxed for 3.5 h. After this period, the mixture is cooled down and excess thionyl chloride is eliminated under reduced pressure while adding portions of toluene. After drying at reduced pressure, 4.67 g of a solid yellowish product corresponding to the acid chloride of interest are obtained. Yield: 100%.
  • Step 2 In a 50 ml glass flask, provided with magnetic agitation and reflux refrigerator, 4.67 g (23.2 mmol) of the acid chloride obtained in the step above are dissolved, under Ar atmosphere, in 25 ml pyridine. The solution is cooled down in a ice bath and 4.44 g (23.2 mmol) of isosorbide 5-mononitrate are added. The reaction mixture is agitated at room temperature under Ar atmosphere for 19 h. After this period the solvent is eliminated at reduced pressure. The residue is dissolved in 50 mL of CHCl 3 and washed: first with 50 mL of water, secondly with 50 mL aqueous solution of 5% HCl and once more with 50 mL water. The organic phase is dried over anhydrous MgSO 4 , filtered, and the solvent is eliminated at reduced pressure. After drying at reduced pressure, 7.25 g of the product of interest are obtained. Yield: 88%.
  • Step 3 In a 250 ml three neck glass flask, provided with a reflux refrigerator closed with a CaCl 2 tube, magnetic agitation, and an addition funnel with a compensated pressure, 6.0 g (16.85 mmol) of the product obtained in the previous step are dissolved in 150 mL of EtOEt. The solution is agitated at room temperature and added, drop by drop, 30 mL of EtOEt solution saturated with HCl (solution prior prepared bubbling HCl gas directly into the EtOEt until saturation), producing a white solid precipitate. The solid is filtered and washed with an excess of EtOEt and dried at reduced pressure. 6.55 g of the product of interest are obtained. Yield: 99%.
  • Step 1 The same method as in step 2 of example 1 is used, applying as starting product the isosorbide 2-mononitrate.
  • the product of interest is obtained at a chemical yield of 88%.
  • Step 2 In a 500 ml three neck glass flask provided with a reflux refrigerator closed with a CaCl 2 tube, magnetic agitation, and a addition funnel with a compensated pressure, 7.0 g (19.66 mmol) of the product obtained in the former step are dissolved in a mixture of 200 mL of EtOEt+100 mL de CH 2 Cl 2 . The solution is agitated at room temperature and added, drop by drop, 30 mL of EtOEt solution saturated with HCl (solution prior prepared bubbling HCl gas directly into the EtOEt until saturatio), producing a white solid precipitate. The solid is filtered and washed with an excess of EtOEt and dried at reduced pressure. 7.05 g of the product of interest are obtained. Yield: 91%.
  • Step 1 In a 100 mL glass flask, provided with a reflux refrigerator closed with a CaCl 2 tube and magnetic agitation, 3.0 g (19.35 mmol) of 2-mercaptonicotinic acid are suspended in 30 mL of thionyl chloride (1.64 g/ml; 431.4 mmol). The mixture is left to reflux for 2 h, observing the dissolution of the solid during this period. The mixture is cooled down and excess thionyl chloride is eliminated under reduced pressure while adding portions of toluene. After drying at reduced pressure, 3.35 g of a solid yellow-orange corresponding to the acid chloride of interest are obtained. Yield, 100%.
  • Step 2 In a 250 mL glass flask, provided with a reflux refrigerator and magnetic agitation, 3.0 g (17.29 mmol) of the acid chloride obtained in the former step are suspended, under Ar atmosphere, in 75 mL of pyridine. The suspension is cooled down in an ice bath and 3.30 g (17.29 mmol) of isosorbide 5-mononitrate are added. The reaction mixture is left agitating at room temperature under Ar atmosphere for 19 h, a period of time wherein the mixture is getting dark. Once the reaction finished, the solvent is eliminated at reduced pressure.
  • the residue is dissolved in 250 mL of CHCl 3 and washed: first with 250 mL of water, secondly with 250 mL aqueous solution of 5% HCl and once more with 250 mL water.
  • the organic phase is dried over anhydrous MgSO 4 , filtered, and the solvent is eliminated at reduced pressure. After drying at reduced pressure, 5.45 g of a yellow solid are obtained, which are recrystallized in isopropanol to obtain 4.83 g of a white solid which is reacted in acid medium for 20 min. with triphenylphosphine (1:1.25 mol/mol) in methanol, with a 10% of water.
  • the solvent is eliminated at reduced presureand the residue is disolved in AcOEt, washing the solution with some water.
  • the organic phase is dried and the solvent is eliminated at reduced presure, recovering the product of interest by preparative chromatography. Yield: 35.7%.
  • the residue is dissolved in 300 mL of CHCl 3 and washed: first with 300 mL of water, secondly with 300 mL aqueous solution of 5% HCl and once more with 300 mL water.
  • the organic phase is dried over anhydrous MgSO 4 , filtered, and the solvent is eliminated at reduced pressure. After drying at reduced temperature, 5.10 g of a white-yellowish solid are obtained, which are re-crystallized in isopropanol to obtain 4.55 g of a white solid which is reacted in acid medium for 20 min. with triphenylphosphine (1:1.25 mol/mol) in methanol, with a 10% of water.
  • the solvent is eliminated at reduced presure and the residue is disolved in AcOEt, washing the solution with some water.
  • the organic phase is dried and the solvent is eliminated at reduced presure, recovering the product of interest by preparative chromatography. Yield: 37.6%.
  • Step 1 In a 1 L glass flask provided with a reflux refrigerator, an addition funnel with a compensated pressure, and magnetic agitation, 60 g (411 mmol) of isomanide, 88 g (461 mmol) of paratoluenesulfonyl chlorine, 296 mL of CCl 4 , 33 mL of CH 2 Cl 2 and 247 mL of H 2 O are mixed. An Ar atmosphere is made and a solution of 29.9 g (453 mmol) of 85% KOH is added, drop by drop, while maintaining the reaction temperature at 5° C. The period of time of the addition is 1 h 20 min. The resulting mixture is agitated at 50 C for 7 h. The solid is filtered and with 2 ⁇ 125 mL portions of H 2 O and dried at reduced pressure.
  • the obtained solid is re-crystallized in 1200 mL of CCl 4 , hot filtered and the filtrate is left to cool down.
  • the obtained crystals are filtered and washed yielding 54.5 g of a fraction A of the product of interest, monotosilate of isomanide.
  • Step 2 In a 500 mL glass flask provided with a reflux refrigerator and magnetic agitation, 22.7 g (76 mmol) of monotosilate of isomanide and 13.0 g (113 mmol) of potassium thioacetate are mixed in 113 mL of n-butanol. An Ar atmosphere is made and the reaction mixture is let to reflux for 1 h. The mixture is cooled down, filtered and washed with 200 mL ethanol and the solvents are eliminated at reduced pressure. 20 g of a solid are obtained.
  • a thin layer chromatographic analysis with independent sample shows that the product of interest is not a major part of the crude.
  • Step 3 A nitrating mixture is prepared by addiing, slowly and carefully, 2.4 ml of 60% HNO 3 into a mixture of 10 mL of acetic anhydride and 10 mL of acetic acid. The mixture is prepared at 0° C.
  • the two compounds tested have a potent vasodilating activity, at least similar to that of the reference, and the compound 1 has a vasodilating activity superior to that of the reference product.
  • the different compounds rested are subcutaneously administrated to rats at a dose of 10 mg/Kg for three days, each eight hours, and the assay is then done ex vivo to test the capacity to vasodilate the arterial segments of the rats after the subcutaneous administration of the compound.
  • the different compounds are tested at 5 different concentrations, at a concentration range from 0.001 to 10 mM, using from 6 to 9 arterial rings for each compound.
  • the obtained results are compared to those from the isosorbide 5-mononitrate, which is used as reference product, and with those obtained from the animals wherein there have not been administrated any compound.
  • CE 50 of isosorbide 5-mononitrate in the group of animals wherein said compound was administrated was seven times superior as compared to that of the not treated animals.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
US09/827,868 1998-10-07 2001-04-06 Derivatives of isosorbide mononitrate and its use as vasodilating agents with reduced tolerance Abandoned US20010051735A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/424,828 US6858632B2 (en) 1998-10-07 2003-04-28 Derivatives of isosorbide mononitrate and its use as vasodilating agents with reduced tolerance

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES009802076A ES2142773B1 (es) 1998-10-07 1998-10-07 Derivados de mononitrato de isosorbida y su empleo como agentes vasodilatadores con tolerancia desminuida.
ESP9802076 1998-10-07
PCT/ES1999/000316 WO2000020420A1 (es) 1998-10-07 1999-10-04 Derivados de mononitrato de isosorbida y su empleo como agentes vasodilatadores con tolerancia disminuida

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES1999/000316 Continuation WO2000020420A1 (es) 1998-10-07 1999-10-04 Derivados de mononitrato de isosorbida y su empleo como agentes vasodilatadores con tolerancia disminuida

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/424,828 Continuation US6858632B2 (en) 1998-10-07 2003-04-28 Derivatives of isosorbide mononitrate and its use as vasodilating agents with reduced tolerance

Publications (1)

Publication Number Publication Date
US20010051735A1 true US20010051735A1 (en) 2001-12-13

Family

ID=8305360

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/827,868 Abandoned US20010051735A1 (en) 1998-10-07 2001-04-06 Derivatives of isosorbide mononitrate and its use as vasodilating agents with reduced tolerance
US10/424,828 Expired - Fee Related US6858632B2 (en) 1998-10-07 2003-04-28 Derivatives of isosorbide mononitrate and its use as vasodilating agents with reduced tolerance

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/424,828 Expired - Fee Related US6858632B2 (en) 1998-10-07 2003-04-28 Derivatives of isosorbide mononitrate and its use as vasodilating agents with reduced tolerance

Country Status (40)

Country Link
US (2) US20010051735A1 (cs)
EP (1) EP1120419B1 (cs)
JP (1) JP4659214B2 (cs)
KR (1) KR100641801B1 (cs)
CN (1) CN1096465C (cs)
AP (1) AP1555A (cs)
AR (1) AR020538A1 (cs)
AT (1) ATE323707T1 (cs)
AU (1) AU762724B2 (cs)
BG (1) BG65135B1 (cs)
BR (1) BR9914355B1 (cs)
CA (1) CA2346010C (cs)
CO (1) CO5180544A1 (cs)
CU (1) CU23162A3 (cs)
CZ (1) CZ294551B6 (cs)
DE (2) DE19983612T1 (cs)
DK (1) DK1120419T3 (cs)
EA (1) EA003360B1 (cs)
EE (1) EE04374B1 (cs)
ES (2) ES2142773B1 (cs)
GB (1) GB2359810B (cs)
GE (1) GEP20043162B (cs)
GT (1) GT199900173A (cs)
HR (1) HRP20010256B1 (cs)
HU (1) HUP0103937A3 (cs)
ID (1) ID29946A (cs)
IL (2) IL142391A0 (cs)
IS (1) IS2312B (cs)
NO (1) NO328584B1 (cs)
NZ (1) NZ510855A (cs)
OA (1) OA11661A (cs)
PA (1) PA8483901A1 (cs)
PE (1) PE20001083A1 (cs)
PL (1) PL200028B1 (cs)
PT (1) PT1120419E (cs)
RS (1) RS50112B (cs)
TR (1) TR200100961T2 (cs)
WO (1) WO2000020420A1 (cs)
YU (1) YU25201A (cs)
ZA (1) ZA200102836B (cs)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100160652A1 (en) * 2008-12-19 2010-06-24 Lacer, S.A. Stereospecific method for the preparation of dioxa-bicyclooctane nitrate compounds

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2258365B1 (es) 2003-10-03 2007-12-01 Lacer, S.A. Derivados de disulfuro, sulfuro, sulfoxido y sulfona de azucares ciclicos y sus usos.
EP1941876A1 (en) * 2006-12-28 2008-07-09 Lacer, S.A. Isosorbide mononitrate derivatives for the treatment of Inflammation and ocular hypertension
ES2332565B1 (es) * 2007-01-23 2010-10-21 Lacer, S.A. Uso de derivados de mononitrato de dianhidrohexita como agentes antiinflamatorios.
IE20070934A1 (en) 2007-12-21 2009-06-24 Trinity College Dublin Efficient aspirin prodrugs
EP2719700A1 (en) 2008-01-09 2014-04-16 Amura Therapeutics Limited Tetrahydrofuro(3,2-b)pyrrol-3-one derivatives as inhibitors of cysteine proteinases
JP5441928B2 (ja) * 2008-02-07 2014-03-12 ニコックス エス エイ 一酸化窒素供与化合物
EP2149576A1 (en) 2008-07-22 2010-02-03 Lacer, S.A. Isosorbide Nitrates having vasodilating activity
EP2149577B1 (en) * 2008-07-22 2011-04-27 Lacer, S.A. New stereospecific method for the preparation of dioxa-bicyclooctane compounds
EP2177216A1 (en) 2008-10-13 2010-04-21 Lacer, S.A. Use of dianhydrohexite mononitrate derivatives as healing agents
WO2010055138A1 (en) * 2008-11-14 2010-05-20 Lacer, S.A. New stereospecific method for the preparation of dioxa-bicyclooctane compounds
ES2423939T3 (es) * 2009-09-10 2013-09-25 Cognis Ip Management Gmbh Derivados de isosorburo gliceril éter y su empleo en aplicaciones de uso doméstico
DK2515899T3 (en) 2009-12-23 2016-08-15 Arca Biopharma Inc METHODS AND COMPOSITIONS FOR CARDIOVASCULAR DISEASES AND CONDITIONS
CN102241687A (zh) * 2011-05-23 2011-11-16 中国人民解放军第四军医大学 抗缺血/再灌注损伤的药物
CA2839390C (en) 2011-10-24 2015-09-15 Nicox S.A. Quinone based nitric oxide donating compounds
CA2902009A1 (en) * 2013-03-05 2014-09-12 Archer Daniels Midland Company Isohexide monotriflates and process for synthesis thereof
WO2014169976A1 (en) 2013-04-18 2014-10-23 Nicox Science Ireland Quinone based nitric oxide donating compounds
CN104650108B (zh) * 2013-11-18 2017-05-24 富力 连翘脂素硫酸酯及其衍生物、制备方法及其应用
CN105461731B (zh) * 2014-08-07 2017-05-24 富力 连翘脂素布洛芬酯、其制备及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1356374A (fr) 1963-02-12 1964-03-27 Machine à fonctions multiples pour le travail du bois
GB1356374A (en) 1971-04-29 1974-06-12 American Home Prod Mononitrate esters of 1,3 3,6-dianhydro-d-glucitol
US3886196A (en) 1973-02-07 1975-05-27 Phillips Petroleum Co Magnesium-aluminum-silicate-phosphate catalysts for ammonialytic cleavage of lactams to form omega-aminonitriles
DE3028289C2 (de) 1980-07-25 1986-11-27 Dr. Willmar Schwabe GmbH & Co, 7500 Karlsruhe 2-O- und 5-O-substituierte 1.4;3.6-Dianhydro-hexit-mononitrate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
DE3248548A1 (de) 1982-12-29 1984-07-05 Heinrich Mack Nachf., 7918 Illertissen Acylderivate von 1,4:3,6-dianhydro-hexiten, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3421072A1 (de) 1984-06-06 1985-12-12 Heinrich Mack Nachf., 7918 Illertissen 1,4:3,6-dianhydro-hexit-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3602067A1 (de) 1986-01-24 1987-07-30 Mack Chem Pharm 2,6-dioxabicyclo(3.3.0)octan-derivate, ihre herstellung und verwendung als arzneimittel
DE3606634A1 (de) 1986-02-28 1987-09-03 Mack Chem Pharm Isohexid-nucleoside, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
IT1204571B (it) * 1987-05-08 1989-03-10 Chiesi Farma Spa Esteri di 1,4:3,6-dianidrosorbitolo-2-mononitrato e 5-mononitrato,loro procedimento di preparazione e loro composizioni farmaceutiche
DE3741005A1 (de) 1987-12-03 1989-06-15 Mack Chem Pharm Aminopropanol-derivate von 1,4:3,6-dianhydro-hexit-nitraten, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JP2628756B2 (ja) * 1988-09-15 1997-07-09 シュバルツファルマ アクチェンゲゼルシャフト 新規有機ニトレート及びそれらの製造方法
US5428061A (en) 1988-09-15 1995-06-27 Schwarz Pharma Ag Organic nitrates and method for their preparation
US4891373A (en) * 1988-11-23 1990-01-02 Pfizer Inc. Aminopropanol derivatives of 1,4:3,6-dianhydrohexitol nitrates, processes for their preparation and their use as medicaments
CA2014520C (en) 1989-04-17 1996-07-16 Fumio Suzuki Hexitol derivatives
NL9001955A (nl) * 1990-09-05 1992-04-01 Cedona Pharm Bv Nieuwe thiazolidinederivaten.
FR2680173A1 (fr) * 1991-08-07 1993-02-12 Hoechst Lab Nitrates organiques, leurs procedes de preparation et leur utilisation dans le traitement de maladies cardiovasculaires .
ATE172183T1 (de) * 1992-07-30 1998-10-15 Cal Int Ltd Ester und kombinationen von einem organischen nitrat und einem salicyclat
IL120531A (en) 1997-03-26 2006-12-31 Yissum Res Dev Co Nitric oxide donors and pharmaceutical compositions containing them

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100160652A1 (en) * 2008-12-19 2010-06-24 Lacer, S.A. Stereospecific method for the preparation of dioxa-bicyclooctane nitrate compounds
US8106224B2 (en) 2008-12-19 2012-01-31 Lacer, S.A. Stereospecific method for the preparation of dioxa-bicyclooctane nitrate compounds

Also Published As

Publication number Publication date
ZA200102836B (en) 2002-09-25
AU6204199A (en) 2000-04-26
CZ20011257A3 (cs) 2001-08-15
PA8483901A1 (es) 2000-09-29
ES2257871T3 (es) 2006-08-01
DE19983612T1 (de) 2001-09-27
EP1120419A1 (en) 2001-08-01
PL347030A1 (en) 2002-03-11
GB2359810B (en) 2003-12-03
CO5180544A1 (es) 2002-07-30
CA2346010C (en) 2010-01-12
JP4659214B2 (ja) 2011-03-30
NZ510855A (en) 2004-02-27
NO328584B1 (no) 2010-03-22
NO20011778D0 (no) 2001-04-06
IS2312B (is) 2007-11-15
EA003360B1 (ru) 2003-04-24
GB2359810A (en) 2001-09-05
AR020538A1 (es) 2002-05-15
DK1120419T3 (da) 2006-07-03
PT1120419E (pt) 2006-07-31
AP1555A (en) 2006-01-18
HRP20010256A2 (en) 2002-04-30
EE04374B1 (et) 2004-10-15
BR9914355B1 (pt) 2014-10-21
HRP20010256B1 (hr) 2009-08-31
CA2346010A1 (en) 2000-04-13
BR9914355A (pt) 2001-06-26
NO20011778L (no) 2001-04-06
TR200100961T2 (tr) 2003-02-21
EP1120419B1 (en) 2006-04-19
HUP0103937A2 (hu) 2002-02-28
ES2142773A1 (es) 2000-04-16
IS5910A (is) 2001-03-29
DE69930949T2 (de) 2006-12-28
ATE323707T1 (de) 2006-05-15
DE69930949D1 (de) 2006-05-24
OA11661A (en) 2004-12-08
CZ294551B6 (cs) 2005-01-12
CN1322205A (zh) 2001-11-14
US20030225134A1 (en) 2003-12-04
EA200100422A1 (ru) 2001-10-22
PL200028B1 (pl) 2008-11-28
RS50112B (sr) 2009-03-25
BG65135B1 (bg) 2007-03-30
JP2002526544A (ja) 2002-08-20
KR100641801B1 (ko) 2006-11-02
US6858632B2 (en) 2005-02-22
IL142391A (en) 2007-07-24
AU762724B2 (en) 2003-07-03
BG105417A (en) 2001-12-29
GT199900173A (es) 2001-03-30
EE200100207A (et) 2002-06-17
AP2001002128A0 (en) 2001-06-30
CN1096465C (zh) 2002-12-18
PE20001083A1 (es) 2000-11-28
GB0111172D0 (en) 2001-06-27
IL142391A0 (en) 2002-03-10
ES2142773B1 (es) 2001-01-01
CU23162A3 (es) 2006-07-18
WO2000020420A1 (es) 2000-04-13
GEP20043162B (en) 2004-01-26
KR20010088848A (ko) 2001-09-28
YU25201A (sh) 2003-04-30
HUP0103937A3 (en) 2003-11-28
ID29946A (id) 2001-10-25

Similar Documents

Publication Publication Date Title
US20010051735A1 (en) Derivatives of isosorbide mononitrate and its use as vasodilating agents with reduced tolerance
CZ294549B6 (cs) Montážní spojka pro úseky vedení kabelů a výsledné úseky vedení kabelů
CN103687843A (zh) 醌基一氧化氮供体化合物
HK1039125A (en) Derivatives of isosorbid mononitrate, utilization as vasodilator agents with reduced tolerance
JP2025513031A (ja) オキサジアゾール化合物、それを含む医薬組成物及びその使用
EP3957638B1 (en) Macrocyclic derivatives acting as xia factor inhibitor
JPH02191271A (ja) １，５―ベンゾオキサチエピン誘導体
JPS5951263A (ja) 硝酸ピリジルアルキルエステル化合物、その製造法およびそれを含有する医薬製剤
MXPA01003568A (en) Derivatives of isosorbid mononitrate, utilization as vasodilator agents with reduced tolerance
JPH08113574A (ja) ピリダジノインドール誘導体
JP3535565B2 (ja) ベンゾピラン誘導体
JPH02247161A (ja) ペンタジエン酸誘導体及びその製造法
JPH0383983A (ja) 硝酸エステル誘導体およびそれを含有する血管拡張剤
JPS5978194A (ja) ２−フエニルイミダゾ〔２，１−ｂ〕ベンゾチアゾ−ルの新規誘導体およびその製造法
JPH0920790A (ja) アスコルビン酸・α−ヒドロキシ酸結合体またはその塩、ならびにその製造方法
JPH04266886A (ja) アザシクロオクタジエン誘導体
JPH03264547A (ja) 酒石酸長鎖アシル誘導体の製造方法
JPH04270291A (ja) チアジノ〔６，５−ｂ〕インドリジン誘導体
JPS62153263A (ja) 三環性又は四環性化合物
JPH0331712B2 (cs)
JPH06220055A (ja) ピロロキノリンキノン誘導体
JPH0692958A (ja) ５−フルオロ−１，３−ジオキシン−４−オン誘導体
JPS60172950A (ja) 新規なアニリン誘導体及びその製法

Legal Events

Date Code Title Description
AS Assignment

Owner name: LACER, S.A., SPAIN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MOLINER, JOSE REPOLLES;COY, FRANCISCO PUBILL;LLORENTE, LYDIA CABEZA;AND OTHERS;REEL/FRAME:011897/0840

Effective date: 20010417

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE